In a diabetic patient who was initially prescribed canagliflozin (Invokana) but switched to empagliflozin (Jardiance) due to insurance denial and now experiences erectile dysfunction, what alternative glucose‑lowering therapies are recommended?

Switch to a Different SGLT2 Inhibitor or Alternative Drug Class

Given that erectile dysfunction with empagliflozin (Jardiance) is likely a class effect of SGLT2 inhibitors, the best option is to switch to a GLP-1 receptor agonist, which offers comparable cardiovascular and renal benefits without the same risk of erectile dysfunction.

Why Not Another SGLT2 Inhibitor

While the evidence on SGLT2 inhibitors and erectile dysfunction is mixed, recent pharmacovigilance data suggests this may be a class effect:

• Dapagliflozin showed significant erectile dysfunction signals in FDA adverse event reporting (reporting odds ratio 1.51) 1
• Empagliflozin also demonstrated erectile dysfunction signals (reporting odds ratio 1.53) 1, though one animal study suggested potential benefit 2
• A direct comparison found empagliflozin had slightly higher rates of genital tract infections and phimosis versus dapagliflozin 3
• Notably, one small pilot study (n=30) found dapagliflozin actually improved erectile dysfunction 4, but this contradicts the larger pharmacovigilance data

The conflicting evidence makes switching to another SGLT2 inhibitor unreliable for resolving erectile dysfunction.

Recommended Alternative: GLP-1 Receptor Agonists

Switch to a GLP-1 receptor agonist (liraglutide, semaglutide, dulaglutide) as the preferred alternative 5. This class offers:

• Cardiovascular benefits comparable to SGLT2 inhibitors - the LEADER trial demonstrated cardiovascular risk reduction 6
• No erectile dysfunction signals - semaglutide showed a signal in one analysis 1, but this is not consistently reported and the mechanism is unclear
• Weight loss benefit (average 3-5 kg), which may independently improve erectile function 5
• No genital mycotic infections unlike SGLT2 inhibitors 7, 8

Second-Line Alternatives if GLP-1 RA Not Tolerated

If GLP-1 receptor agonists cause intolerable gastrointestinal side effects:

1. DPP-4 inhibitors (sitagliptin, linagliptin) - weight neutral, well-tolerated, though sitagliptin showed erectile dysfunction signals in one analysis 1. Linagliptin did not show signals and may be preferable.

2. Pioglitazone - if no contraindications (heart failure, bladder cancer history, osteoporosis risk). Weight gain is a concern but no erectile dysfunction association 5.

3. Basal insulin - if glycemic control is inadequate. Does not cause erectile dysfunction but requires careful titration to avoid hypoglycemia 5.

Critical Pitfalls to Avoid

• Do not assume all SGLT2 inhibitors are equivalent for erectile dysfunction - while class effects exist, individual variation occurs
• Screen for other erectile dysfunction causes - testosterone deficiency (check total testosterone), uncontrolled hyperglycemia (A1C >9%), peripheral neuropathy, and cardiovascular disease all contribute independently 9
• Consider PDE5 inhibitor therapy (sildenafil, tadalafil) regardless of diabetes medication choice - these remain first-line for erectile dysfunction treatment even in diabetes 9
• Avoid metformin monotherapy if cardiovascular disease present - while metformin doesn't cause erectile dysfunction, it lacks the cardiovascular protection of GLP-1 RAs or SGLT2 inhibitors 5

Addressing the Insurance Issue

If insurance denied canagliflozin but approved empagliflozin, they will likely approve:

• GLP-1 receptor agonists with prior authorization citing adverse effect (erectile dysfunction) to empagliflozin
• Document the adverse effect clearly in medical records
• Emphasize cardiovascular risk reduction as indication per ADA/EASD guidelines 5